Comprehensive Overview of the Cowingene Group B Streptococcus Detection Kit (Lyophilized)

As global healthcare systems continue to emphasize maternal and neonatal safety, early and accurate screening for infectious diseases during pregnancy has become a critical component of prenatal care. Among the most important pathogens in this context is Group B Streptococcus (GBS), a bacterium that can be harmless in adults but potentially life-threatening for newborns. To address this clinical need, the Cowingene Group B Streptococcus Detection Kit (Lyophilized) provides a sensitive, stable, and efficient molecular diagnostic solution designed specifically for prenatal screening.

1. Company Background and Innovation Commitment

As part of a broader molecular diagnostics innovation ecosystem, we specialize in developing and manufacturing molecular POCT in vitro diagnostic reagents. With a professional team and a spirit of innovation, we are committed to advancing health management to be more efficient, accessible, and intelligent—becoming a trusted partner in the field of molecular diagnostics.

Driven by this mission, the development of advanced nucleic acid testing solutions such as the Cowingene GBS Detection Kit reflects our commitment to improving maternal health outcomes and strengthening preventive healthcare systems worldwide.

2. Product Overview

The Cowingene GBS Detection Kit is an in vitro diagnostic (IVD) assay based on real-time PCR technology. It is designed for the qualitative detection of:

• Group B Streptococcus infection (GBS)

The kit is intended for use with female vaginal swab samples and is optimized for prenatal screening, particularly during late pregnancy.

It adopts a lyophilized (freeze-dried) format, which enhances reagent stability, simplifies storage conditions, and improves usability in different laboratory environments.

3. Clinical Significance of GBS Screening

Group B Streptococcus is a common bacterium found in the gastrointestinal and genital tracts of healthy adults. While typically harmless in carriers, it poses a significant risk during pregnancy.

GBS is one of the leading causes of:

• Neonatal sepsis
• Pneumonia in newborns
• Meningitis in infants
• Early-onset neonatal infections within the first week of life

Without proper screening and intervention, vertical transmission from mother to newborn during childbirth can lead to severe complications or even mortality.

For this reason, clinical guidelines strongly recommend screening pregnant women between 36 and 37 weeks of gestation to determine the need for intrapartum antibiotic prophylaxis.

4. Intended Use and Clinical Application

The Cowingene GBS Detection Kit is intended for the in vitro qualitative detection of Group B Streptococcus in vaginal swab samples. It plays a key role in prenatal care by identifying maternal colonization status before delivery.

Its primary clinical purposes include:

• Identifying GBS colonization in pregnant women
• Supporting prevention strategies for neonatal infection
• Guiding antibiotic prophylaxis during labor
• Enhancing maternal-fetal health outcomes
• Supporting obstetric risk management decisions

Early detection ensures that appropriate preventive measures can be taken to protect newborns from early-onset GBS disease.

5. Detection Technology

The kit utilizes real-time polymerase chain reaction (PCR) combined with fluorescent probe technology, which is widely regarded as one of the most accurate molecular diagnostic methods.

Detection Principle

1. Extraction of nucleic acid from vaginal swab samples
2. Amplification of GBS-specific conserved gene regions
3. Detection using fluorescent probes during amplification cycles
4. Interpretation of results based on fluorescence signals
5. Quality control verification using internal control genes

The assay targets conserved genomic regions specific to Group B Streptococcus, ensuring high specificity and reliability.

6. Internal Quality Control System

A key feature of this kit is the inclusion of an endogenous internal control. This control system:

• Verifies sample quality
• Monitors nucleic acid extraction efficiency
• Detects potential PCR inhibition
• Ensures overall test validity

This significantly improves diagnostic reliability and reduces the risk of false-negative results caused by poor sample quality or technical errors.

7. Analytical Performance

Sensitivity (Limit of Detection)

The kit has a Limit of Detection (LoD) of 400 copies/mL for GBS, enabling detection even at low bacterial loads.

Specificity

The assay specifically targets conserved genetic sequences unique to Group B Streptococcus, minimizing cross-reactivity with other vaginal microbiota.

Precision

The system demonstrates strong repeatability and reproducibility, ensuring consistent results across different operators, instruments, and laboratory conditions.

8. Lyophilized Formulation Advantages

Unlike liquid reagents, this kit uses a lyophilized (freeze-dried) format, offering several advantages:

• Improved long-term stability
• Reduced cold-chain dependency
• Easier transportation and storage
• Enhanced reagent consistency
• Reduced risk of degradation

This makes the kit particularly suitable for laboratories in diverse environmental conditions or resource-limited settings.

9. Sample Type and Collection

The kit is validated exclusively for:

• Female vaginal swab samples

To support proper sample collection, compatible self-collection kits are available, allowing:

• Increased patient comfort
• Improved screening compliance
• Reduced clinical workload
• Broader access to prenatal testing

Self-sampling also supports community-based prenatal screening programs.

10. Instrument Compatibility

The assay is compatible with a wide range of open real-time PCR platforms, including:

• ABI 7500
• Roche LightCycler 480
• Bio-Rad CFX96

It supports multiple fluorescence detection channels such as FAM, VIC/HEX, ROX, and CY5, enabling seamless integration into existing laboratory systems.

11. Storage and Stability

The Cowingene GBS Detection Kit has flexible storage conditions:

• Storage temperature: 2–30°C
• Shelf life: up to 18 months

Additional Handling Requirements:

• Transport at 2–30°C for up to 15 days
• Protect from light exposure
• Once opened, buffer components are stable for limited periods under refrigeration
• Repeated freeze-thaw cycles should be minimized

These conditions make the kit highly practical for routine clinical use.

12. Clinical Workflow Integration

To ensure optimal performance, the kit is supported by a complete molecular diagnostic workflow system, including:

• Nucleic acid extraction kits
• Sample release reagents
• DNA/RNA purification columns
• Self-collection vaginal sampling kits

This integrated ecosystem ensures consistency and reproducibility across all testing stages.

13. Clinical Applications

The Cowingene GBS Detection Kit is primarily used in:

1. Prenatal Screening Programs

Routine screening of pregnant women during late gestation.

2. Obstetric Care

Risk assessment and intrapartum antibiotic decision-making.

3. Hospital Laboratories

Molecular diagnostic support for maternal health management.

4. Public Health Programs

Prevention of neonatal infections and monitoring of maternal colonization rates.

14. Advantages of the Cowingene GBS Detection System

High Sensitivity

Detects low levels of bacterial colonization effectively.

High Specificity

Targets conserved GBS genes to ensure accurate identification.

Internal Control System

Ensures result validity and reduces false negatives.

Lyophilized Stability

Enhances storage flexibility and transport convenience.

Workflow Compatibility

Integrates easily into existing PCR laboratory systems.

Clinical Relevance

Supports evidence-based prevention of neonatal GBS disease.

15. Public Health Importance

GBS infection remains a leading cause of preventable neonatal morbidity and mortality worldwide. Many cases of early-onset neonatal infection can be avoided through timely maternal screening and antibiotic prophylaxis.

The use of molecular diagnostic tools such as this kit enables:

Early identification of carriers

Timely clinical intervention

Reduced neonatal infection rates

Improved maternal-fetal health outcomes

This aligns with global efforts to reduce preventable neonatal diseases.

 Conclusion

The Cowingene Group B Streptococcus Detection Kit (Lyophilized) represents a highly reliable molecular diagnostic solution designed for prenatal screening and neonatal infection prevention. By combining real-time PCR technology, lyophilized reagent stability, and internal quality control systems, it delivers accurate and consistent detection of Group B Streptococcus in clinical samples.

Supported by the philosophy that we specialize in developing and manufacturing molecular POCT in vitro diagnostic reagents. With a professional team and a spirit of innovation, we are committed to advancing health management to be more efficient, accessible, and intelligent—becoming a trusted partner in the field of molecular diagnostics, this product contributes significantly to improving maternal and neonatal healthcare outcomes.

Through early detection and effective prevention strategies, the kit plays an essential role in reducing neonatal infection risks and advancing global prenatal screening standards.